The Monogram acquisition will contribute to revenue growth in 2027 by improving Zimmer Biomet's robotic knee adoption in the ...

Secondary firm Committed Advisors served as lead investor in a continuation vehicle used to acquire meat snack manufacturer ...

AUSTIN, TEXAS / ACCESS Newswire / July 8, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) (“Monogram” or the “Company”), an ...

On March 17, 2025, Monogram (NASDAQ:MGRM) announced that the FDA has granted 510 (k) clearance for its Monogram mBôs TKA System. This determination means that the company can move forward with ...

Monogram has obtained FDA 510 (k) clearance for its mBôs TKA System and FDA clearance for its mPress implants. The Company is required to obtain FDA clearance before it can market its products.

Management believes the feedback was comprehensive and will be advantageous for a successful 510 (k) submission to obtain clearance, commercialization, and marketing for the mBôs™ TKA System.

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT FDA Response to 510 (k) Filing On October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information ...

Ben Sexson, Monogram Chief Executive Officer, commented, "This FDA 510 (k) clearance is a defining moment for Monogram. It marks the culmination of years of relentless effort, innovation, and ...

Monogram has obtained FDA clearance for mPress implants and applied for 510 (k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products.

Monogram has obtained FDA 510 (k) clearance for its mBôs TKA System and FDA clearance for its mPress implants. The Company is required to obtain FDA clearance before it can market its products.